Dostarlimab clinical trials
Also written TSR-042, Jemperli and ANB011.
ClinicalTrials.gov finds 108 studies for dostarlimab. How that becomes 77 here
Every study that search finds has been read, to see whether and how it gives dostarlimab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 108Found by its intervention search · See all 108 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 95 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- 108Give dostarlimab to participants
- −5Observe patients on it, or give it outside a trial
- −26Give it beside what is tested
- 77Test it: the count on this site
Get an email when these change. Save the dostarlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Apr 2021 · JEMPERLI · BLA 761174 (FDA, Drugs@FDA)
- European Union
- 21 Apr 2021 · Jemperli · EMEA/H/C/005204 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
77 studies that test it; most in 2023 (12)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 9 |
| 2020 | 11 |
| 2021 | 11 |
| 2022 | 2 |
| 2023 | 12 |
| 2024 | 10 |
| 2025 | 10 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 51
GlaxoSmithKline (17) · Tesaro, Inc. (8) · M.D. Anderson Cancer Center (3) · ARCAGY/ GINECO GROUP (2) · Grupo Español de Investigación en Cáncer de Ovario (2) · Massachusetts General Hospital (2) · Memorial Sloan Kettering Cancer Center (2) · University of Oklahoma (1)
Often tested with
Tested in the same studies.
Niraparib (20) · Bevacizumab (3) · Carboplatin (3) · Paclitaxel (3) · Cobolimab (3) · Atezolizumab (3) · Pembrolizumab (2) · Carboplatin/Paclitaxel Regimen (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 8 most studied
New when their studies opened, with dostarlimab beside them; studies of each.
Reaching primary completion within a year · 17, 2 in phase 3
Studies that test dostarlimab, phase 3 first.
- Nov 2026A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerPhase 3 · Tesaro, Inc.
- Jun 2027Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibPhase 2/3 · ARCAGY/ GINECO GROUP
- Nov 2026Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaPhase 2 · H. Lee Moffitt Cancer Center and Research Institute
- Nov 2026A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal CancerPhase 2 · GlaxoSmithKline
- Nov 2026A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerPhase 2 · GlaxoSmithKline
- Nov 2026Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerPhase 2 · GlaxoSmithKline
- Jan 2027A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)Phase 4 · GlaxoSmithKline
- Feb 2027Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive SurgeryPhase 2 · Memorial Sloan Kettering Cancer Center
- Feb 2027Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerPhase 2 · Massachusetts General Hospital
Studies
Open first, then newest update. How each study uses dostarlimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 77
- A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerNot yet recruitingPhase 3GlaxoSmithKlineNCT07740720Given for longer in dMMR rectal cancerWritten as DostarlimabReport a problem
- Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial CancerRecruitingPhase 3UNC Lineberger Comprehensive Cancer CenterNCT07867002One or two years of maintenance, with pembrolizumab or dostarlimabReport a problem
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04165772On the US labelInduction alone in mismatch repair-deficient tumoursWritten as TSR-042 or DostarlimabReport a problem
- Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingPhase 3GlaxoSmithKlineNCT07860450Under the skin against into a vein, in endometrial cancerWritten as DostarlimabReport a problem
- Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive SurgeryRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04774419With radiotherapy after surgery for MMR-deficient endometrial cancerWritten as DostarlimabReport a problem
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingPhase 2/3ARCAGY/ GINECO GROUPNCT03651206Added to niraparib in recurrent carcinosarcomaWritten as Niraparib + TSR-042 (Dostarlimab)Report a problem
- DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II StudyRecruitingPhase 2GERCOR - Multidisciplinary Oncology Cooperative GroupNCT06059495Alone, then watch-and-wait, in dMMR gastric cancerWritten as DostarlimabReport a problem
- Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical CarcinomaRecruitingPhase 2Chang Gung Memorial HospitalNCT07336147Added to chemoradiation in small cell neuroendocrine cervical cancerWritten as DostarlimabReport a problem
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingPhase 4GlaxoSmithKlineNCT07652515With carboplatin-paclitaxel, safety in Indian patientsWritten as DostarlimabReport a problem
- Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon CancersRecruitingPhase 2University of IowaNCT05239546Neoadjuvant alone in dMMR colon cancerWritten as DostarlimabReport a problem
- Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT05819892Maintenance after chemoradiation and chemotherapy in endometrial cancerWritten as DostarlimabReport a problem
- A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaRecruitingPhase 3GlaxoSmithKlineNCT06256588Against placebo after chemoradiation in head and neck cancerWritten as DostarlimabReport a problem
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerRecruitingPhase 2GlaxoSmithKlineNCT06567782Added to CAPEOX before surgery in MMR-proficient colon cancerWritten as DostarlimabReport a problem
- Cabozantinib and Dostarlimab in Recurrent Gynecologic CarcinosarcomaRecruitingPhase 1/2University of Alabama at BirminghamNCT05559879With cabozantinib in recurrent gynaecologic carcinosarcomaWritten as Cabo + DostarlimabReport a problem
- Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon CancerRecruitingPhase 2Universitaire Ziekenhuizen KU LeuvenNCT06830239Alone before surgery in MMR-proficient colon cancerWritten as DostarlimabReport a problem
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05700721With niraparib for progressing brain metastasesWritten as DostarlimabReport a problem
- XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) PatientsNot yet recruitingPhase 2Gruppo Oncologico Italiano di Ricerca ClinicaNCT07381777Added to XELOX after chemoradiation in MMR-proficient rectal cancerWritten as DostarlimabReport a problem
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerRecruitingPhase 3GlaxoSmithKlineNCT05855200Perioperative, against standard care in dMMR colon cancerWritten as DostarlimabReport a problem
- A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)RecruitingPhase 2GlaxoSmithKlineNCT07108270With carboplatin-paclitaxel in Chinese patients with endometrial cancerWritten as DostarlimabReport a problem
- Impact of Circadian Rhythm on ImmunotherapyRecruitingPhase 2Liza Villaruz, MDNCT07224971One PD-1 option, given in the morning or the afternoonReport a problem
See all 77 studies that test dostarlimab →
Behind its US label · 4 — the studies the FDA label of JEMPERLI describes
From the Clinical Studies section of JEMPERLI (2026-10), as openFDA has it. A study the site does not hold is left out.
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsActive, not recruitingPhase 1Tesaro, Inc.NCT02715284Report a problem
- A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerActive, not recruitingPhase 3Tesaro, Inc.NCT03981796Report a problem
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04165772Report a problem
- A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal CancerActive, not recruitingPhase 2GlaxoSmithKlineNCT05723562Report a problem
Tested on its own · 20 — no other medicine in its arm
- A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerNot yet recruitingPhase 3GlaxoSmithKlineNCT07740720Given for longer in dMMR rectal cancerWritten as DostarlimabReport a problem
- Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive SurgeryRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04774419With radiotherapy after surgery for MMR-deficient endometrial cancerWritten as DostarlimabReport a problem
- DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II StudyRecruitingPhase 2GERCOR - Multidisciplinary Oncology Cooperative GroupNCT06059495Alone, then watch-and-wait, in dMMR gastric cancerWritten as DostarlimabReport a problem
- Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical CarcinomaRecruitingPhase 2Chang Gung Memorial HospitalNCT07336147Added to chemoradiation in small cell neuroendocrine cervical cancerWritten as DostarlimabReport a problem
- Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon CancersRecruitingPhase 2University of IowaNCT05239546Neoadjuvant alone in dMMR colon cancerWritten as DostarlimabReport a problem
- A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaRecruitingPhase 3GlaxoSmithKlineNCT06256588Against placebo after chemoradiation in head and neck cancerWritten as DostarlimabReport a problem
- Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon CancerRecruitingPhase 2Universitaire Ziekenhuizen KU LeuvenNCT06830239Alone before surgery in MMR-proficient colon cancerWritten as DostarlimabReport a problem
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerRecruitingPhase 3GlaxoSmithKlineNCT05855200Perioperative, against standard care in dMMR colon cancerWritten as DostarlimabReport a problem
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIRecruitingPhase 2UNICANCERNCT06333314Alone against chemotherapy in dMMR cancers beyond colon and endometriumWritten as DostarlimabReport a problem
- pReOperative Dostarlimab and Novel Therapies in EndOmetrial CancerNot yet recruitingPhase 2University College, LondonNCT07115927Alone before surgery in high-risk endometrial cancerWritten as DostarlimabReport a problem
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)Not yet recruitingPhase 4GlaxoSmithKlineNCT06897527Safety alone in Indian patients with endometrial cancerWritten as DostarlimabReport a problem
- Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial CancerNot yet recruitingPhase 2Grupo Español de Investigación en Cáncer de OvarioNCT07013851Alone before surgery in dMMR endometrial cancerWritten as DostarlimabReport a problem
- PREventing Second Cancers With DOSTARlimabRecruitingPhase 2Centre Leon BerardNCT05855811To prevent second cancers after curative treatmentWritten as DostarlimabReport a problem
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsActive, not recruitingPhase 1Tesaro, Inc.NCT02715284On the US labelFirst-in-human doses, then endometrial and other cohortsWritten as DostarlimabReport a problem
- TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiationActive, not recruitingPhase 2Grupo Español de Investigación en Cáncer de OvarioNCT03833479Maintenance after chemoradiation in cervical cancerWritten as TSR-042Report a problem
- A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal CancerActive, not recruitingPhase 2GlaxoSmithKlineNCT05723562On the US labelAlone in dMMR locally advanced rectal cancerWritten as DostarlimabReport a problem
- TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial CancerActive, not recruitingPhase 1Washington University School of MedicineNCT03955978Added to radiotherapy for inoperable endometrial cancerWritten as TSR-042Report a problem
- A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in ChinaActive, not recruitingPhase 2GlaxoSmithKlineNCT06640049Alone in dMMR rectal cancer in ChinaWritten as DostarlimabReport a problem
- Study on TSR-042 in Advanced Clear Cell SarcomaTerminatedPhase 2Italian Sarcoma GroupNCT04274023Alone in advanced clear cell sarcomaWritten as TSR-042Report a problem
- Dostarlimab in Chemoresistant Gestational Trophoblastic NeoplasiaWithdrawnPhase 2University of MiamiNCT05405192Alone in chemoresistant gestational trophoblastic neoplasiaWritten as DostarlimabReport a problem
Tested with established drugs · 19 — they are given beside it
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingPhase 4GlaxoSmithKlineNCT07652515With carboplatin-paclitaxel, safety in Indian patientsWritten as DostarlimabReport a problem
- Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT05819892Maintenance after chemoradiation and chemotherapy in endometrial cancerWritten as DostarlimabReport a problem
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerRecruitingPhase 2GlaxoSmithKlineNCT06567782Added to CAPEOX before surgery in MMR-proficient colon cancerWritten as DostarlimabReport a problem
- XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) PatientsNot yet recruitingPhase 2Gruppo Oncologico Italiano di Ricerca ClinicaNCT07381777Added to XELOX after chemoradiation in MMR-proficient rectal cancerWritten as DostarlimabReport a problem
- SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)RecruitingPhase 2Queensland Centre for Gynaecological CancerNCT06278857Alone, in place of surgery, for early dMMR endometrial cancerWritten as Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]Report a problem
- Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix CancerActive, not recruitingPhase 2University of OklahomaNCT04068753With niraparib in recurrent cervical cancerWritten as dostarlimabReport a problem
- Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in MelanomaActive, not recruitingPhase 2Diwakar DavarNCT04139902Alone or with cobolimab before melanoma surgeryWritten as Dostarlimab (TSR-042) (singly)Report a problem
- Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04701307With niraparib in small cell lung and neuroendocrine carcinomasWritten as DostarlimabReport a problem
- Niraparib + Dostarlimab In BRCA Mutated Breast CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT04584255With niraparib before surgery in BRCA-mutated breast cancerWritten as DostarlimabReport a problem
- Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic CancerCompletedPhase 2Mayo ClinicNCT04493060With niraparib in BRCA- or PALB2-mutated pancreatic cancerWritten as DostarlimabReport a problem
- Study of Niraparib and TSR-042 in Recurrent Endometrial CancerActive, not recruitingPhase 2University Health Network, TorontoNCT03016338With niraparib in recurrent endometrial cancerWritten as TSR-042Report a problem
- Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCCCompletedPhase 2Trisha Wise-DraperNCT04313504With niraparib in head and neck cancerWritten as DostarlimabReport a problem
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingPhase 1/2GlaxoSmithKlineNCT04126200Added to belantamab mafodotin in one myeloma sub-studyWritten as DostarlimabReport a problem
- Niraparib + Dostarlimab + RT in Pancreatic CancerCompletedPhase 2Massachusetts General HospitalNCT04409002With niraparib and radiotherapy in pancreatic cancerWritten as DostarlimabReport a problem
- Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)TerminatedPhase 2GlaxoSmithKlineNCT04581824With chemotherapy against pembrolizumab plus chemotherapy in lung cancerWritten as DostarlimabReport a problem
- A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian CancerCompletedPhase 2Tesaro, Inc.NCT03574779With niraparib and bevacizumab in platinum-resistant ovarian cancerWritten as TSR-042Report a problem
- Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedPhase 2Tesaro, Inc.NCT05751629With bevacizumab and niraparib in recurrent ovarian cancerWritten as DostarlimabReport a problem
- Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerTerminatedPhase 2Tesaro, Inc.NCT03955471With niraparib in platinum-resistant ovarian cancerWritten as DostarlimabReport a problem
- Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentStatus unknownPhase 3Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT04679064With niraparib against chemotherapy in recurrent ovarian cancerWritten as DostarlimabReport a problem
Tested in a combination · 38 — another drug in the study is under test too
- Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial CancerRecruitingPhase 3UNC Lineberger Comprehensive Cancer CenterNCT07867002One or two years of maintenance, with pembrolizumab or dostarlimabReport a problem
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04165772On the US labelInduction alone in mismatch repair-deficient tumoursWritten as TSR-042 or DostarlimabReport a problem
- Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingPhase 3GlaxoSmithKlineNCT07860450Under the skin against into a vein, in endometrial cancerWritten as DostarlimabReport a problem
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingPhase 2/3ARCAGY/ GINECO GROUPNCT03651206Added to niraparib in recurrent carcinosarcomaWritten as Niraparib + TSR-042 (Dostarlimab)Report a problem
- Cabozantinib and Dostarlimab in Recurrent Gynecologic CarcinosarcomaRecruitingPhase 1/2University of Alabama at BirminghamNCT05559879With cabozantinib in recurrent gynaecologic carcinosarcomaWritten as Cabo + DostarlimabReport a problem
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05700721With niraparib for progressing brain metastasesWritten as DostarlimabReport a problem
- A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)RecruitingPhase 2GlaxoSmithKlineNCT07108270With carboplatin-paclitaxel in Chinese patients with endometrial cancerWritten as DostarlimabReport a problem
- Impact of Circadian Rhythm on ImmunotherapyRecruitingPhase 2Liza Villaruz, MDNCT07224971One PD-1 option, given in the morning or the afternoonReport a problem
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05526989With niraparib in penile carcinomaWritten as DostarlimabReport a problem
- DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic CancerRecruitingPhase 2Hopital FochNCT06757244With vitamin D3 and mFOLFIRINOX in metastatic pancreatic cancerWritten as DostarlimabReport a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956Off-label use in one biomarker-matched armReport a problem
- Niraparib and Dostarlimab in HRD Solid TumorsRecruitingPhase 2West Cancer CenterNCT04983745With niraparib in HRD-mutated solid tumoursReport a problem
- Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCCRecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT04681469With niraparib before surgery in HPV-negative head and neck cancerReport a problem
- Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First LineActive, not recruitingPhase 3ARCAGY/ GINECO GROUPNCT05201547Alone against chemotherapy in MMR-deficient endometrial cancerWritten as DostarlimabReport a problem
- A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)Active, not recruitingPhase 2Yonsei UniversityNCT06023862Alone or with bevacizumab, against chemotherapy in clear cell gynaecologic cancerWritten as DostarlimabReport a problem
- A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerActive, not recruitingPhase 2GlaxoSmithKlineNCT06317311With carboplatin-paclitaxel in Japanese patients with endometrial cancerWritten as DostarlimabReport a problem
- Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingPhase 1University of WashingtonNCT04673448With niraparib in BRCA-mutated cancersWritten as DostarlimabReport a problem
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedPhase 2University of LeicesterNCT03654833With niraparib in one mesothelioma armWritten as Dostarlimab and NiraparibReport a problem
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)Active, not recruitingPhase 3GlaxoSmithKlineNCT06472076With belrestotug, against pembrolizumab, in PD-L1 high lung cancerWritten as DostarlimabReport a problem
- Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyActive, not recruitingPhase 2/3GlaxoSmithKlineNCT04655976With docetaxel, with or without cobolimab, against docetaxelWritten as DostarlimabReport a problem
Showing 20 of 38. See all 38 →
Beside an established treatment under test · 2 — an approved drug, surgery or radiation is what the study tests
Tested with dostarlimab: Radiation 2 · niraparib 1
- PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer PatientsRecruitingPhase 3Centre Hospitalier Universitaire DijonNCT06762405In every armGiven in both arms; the study tests adding short-course radiotherapyWritten as DostarlimabReport a problem
- A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal CancersTerminatedPhase 1University of IowaNCT04926324In every armFixed dose beside escalating niraparib and radiotherapyWritten as DostarlimabReport a problem
Beside a new treatment under test · 20 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with dostarlimab: belrestotug 6 · nelistotug 6 · cobolimab 4 · risvutatug rezetecan 3 · remzistotug 2 · feladilimab 2 · roginolisib 1 · inupadenant 1
- A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)RecruitingPhase 1/2GlaxoSmithKlineNCT06796907Partner of new Mo-Rez in endometrial cancerWritten as DostarlimabReport a problem
- A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingPhase 2University Health Network, TorontoNCT07408063Partner of new risvutatug rezetecan in head and neck cancerWritten as DostarlimabReport a problem
- Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06065462In every armPartner of new LB-100 in ovarian clear cell carcinomaWritten as DostarlimabReport a problem
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingPhase 1GlaxoSmithKlineNCT06551142Partner of new Ris-Rez in one combination armWritten as DostarlimabReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Partner of new agents in two I-SPY armsWritten as Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabReport a problem
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerActive, not recruitingPhase 2GlaxoSmithKlineNCT05565378Backbone for new belrestotug and nelistotug, beside pembrolizumabWritten as DostarlimabReport a problem
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT05277051Partner of new remzistotug, belrestotug and othersWritten as DostarlimabReport a problem
- A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Active, not recruitingPhase 2GlaxoSmithKlineNCT06062420In every armBackbone for new belrestotug, nelistotug and remzistotug in head and neck cancerWritten as DostarlimabReport a problem
- A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid TumorsTerminatedPhase 1GlaxoSmithKlineNCT03843359Partner of new STING agonist GSK3745417Written as DostarlimabReport a problem
- A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) PatientsActive, not recruitingPhase 1/2iOncturaNCT06879717In every armBackbone for new roginolisib in lung cancerWritten as DostarlimabReport a problem
- Dostarlimab and Cobolimab in Advanced Cervical CancerActive, not recruitingPhase 2Meghan SheaNCT06238635In every armPartner of new cobolimab in cervical cancerWritten as DostarlimabReport a problem
- Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2TerminatedPhase 1Elevation OncologyNCT05980416Partner of new EO-3021 in one combination armWritten as DostarlimabReport a problem
- A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerActive, not recruitingPhase 1/2GlaxoSmithKlineNCT06521567In every armPartner of new cobolimab in children and young adultsWritten as DostarlimabReport a problem
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingPhase 1Tesaro, Inc.NCT02817633Partner of new cobolimab in combination armsWritten as TSR-042Report a problem
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT04446351Partner of new GSK6097608, belrestotug and cobolimabWritten as DostarlimabReport a problem
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3CompletedPhase 2GlaxoSmithKlineNCT06926673In every armBackbone for new belrestotug and nelistotug in lung cancerWritten as DostarlimabReport a problem
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2GlaxoSmithKlineNCT03739710Partner of new belrestotug in lung cancer armsWritten as DostarlimabReport a problem
- Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)CompletedPhase 1GlaxoSmithKlineNCT02723955Partner of new feladilimab in one armWritten as DostarlimabReport a problem
- Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsActive, not recruitingPhase 1/2iTeos Belgium SANCT05060432Partner of new belrestotug or inupadenantWritten as DostarlimabReport a problem
- Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsCompletedPhase 1Tesaro, Inc.NCT03250832Partner of new TSR-033 in combination armsWritten as DostarlimabReport a problem
Beside supportive care · 1 — a supportive treatment or test is studied
- Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)TerminatedPhase 1/2GlaxoSmithKlineNCT06405230Standard treatment while biomarker tools are tested in lung cancerWritten as DostarlimabReport a problem
One option of several · 3 — a test or a strategy chooses among drugs
- A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)RecruitingPhase 3GlaxoSmithKlineNCT07684599In every armOne immunotherapy choice in both arms; new Mo-Rez is addedWritten as DostarlimabReport a problem
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingPhase 2University Health Network, TorontoNCT05065021One drug in biomarker-guided regimens after PARP inhibitorsWritten as DostarlimabReport a problem
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingPhase 1University of Southern CaliforniaNCT04387084In every armOne PD-1 option beside short-term fasting under testWritten as DostarlimabReport a problem
Observed · 5 — patients on it are followed, or it is given outside a trial
- Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line TreatmentNot yet recruitingChirecNCT07545486Part of first-line endometrial cancer treatment before ablative therapyReport a problem
- Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal CancerRecruitingNational Cancer Institute, NaplesNCT07269249Before surgery in dMMR rectal cancer, observed in an Italian registryWritten as DostarlimabReport a problem
- Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.Not yet recruitingFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06797479One of three PD-1 antibodies measured in patients' bloodReport a problem
- DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial CancerRecruitingGrupo Español de Investigación en Cáncer de OvarioNCT05728814Real-world use in the Spanish expanded access programmeWritten as DostarlimabReport a problem
- EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance DatabaseCompletedGroupe Hospitalier Pitie-SalpetriereNCT05934214One checkpoint option in the WHO adverse event databaseReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call dostarlimab · ClinicalTrials.gg INT001720
- MeSH (NLM) C000719628dostarlimabOne source ClinicalTrials.gov
- UNII (FDA) P0GVQ9A4S5DOSTARLIMABConfirmed FDA, Wikidata
- RxNorm 2539967One source FDA
- Wikidata Q85757472dostarlimabConfirmed FDA, Wikidata
- NCI Thesaurus C126799DostarlimabOne source FDA
- DrugBank DB15627One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719628 | dostarlimab | One source ClinicalTrials.gov |
| UNII (FDA) | P0GVQ9A4S5 | DOSTARLIMAB | Confirmed FDA, Wikidata |
| RxNorm | 2539967 | — | One source FDA |
| Wikidata | Q85757472 | dostarlimab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C126799 | Dostarlimab | One source FDA |
| DrugBank | DB15627 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.